News

Bristol-Myers Squibb Company and Nektar Therapeutics collaborate commercially for Nektar's lead immuno-oncology program, NKTR-214. The companies will jointly develop and…
Read More...

OTTR, the leading provider of organ transplant patient tracking software that improves the quality of patient care via workflow management, has partnered with Hemasoft, an international…
Read More...

IRX Therapeutics asserted that Phase 2 double-blind, randomized, placebo-controlled clinical trial of IRX-2 in women has commenced with squamous cervical intraepithelial neoplasia 3…
Read More...

Neurocrine Biosciences announced that the US FDA has provided assistance on the regulatory path forward to support the New Drug Application for opicapone, an investigational drug for…
Read More...

Novartis division, Sandoz asserted that the US FDA ha sanctioned the roll out and launch of Glatopa (glatiramer acetate injection) 40 mg/mL. Glatopa was developed under a…
Read More...

Roche asserted that it has received FDA clearance for the cobas Factor II and Factor V Test for use on the cobas 4800 system. The test enables laboratories to simultaneously evaluate …
Read More...

FDA has approved a certain Erleada for the treatment of patient inflicted with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the approval of ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of…
Read More...

Mallinckrodt plc  confirmed the enrollment of first patient for the company's Phase 1 study evaluating the safety and tolerance of ExpressGraft C9T1 skin tissue in the treatment of…
Read More...

Division of Valeant Pharmaceuticals International, Inc., Ortho Dermatologics asserted that the U.S Food and Drug Administration accepted the New Drug Application for JEMDEL  …
Read More...

PharmaMar forays into an exclusive licensing agreement with Seattle Genetics ensuring access to certain PharmaMar proprietary molecules for the development and commercialization of…
Read More...

Amgen asserted that the Oncologic Drugs Advisory Committee of the U.S Food and Drug Administration will assess the data supporting the BLINCYTO supplemental Biologics License…
Read More...

Ace RNA medicines company, Arcturus Therapeutics asserted the appointment of Dr. Christine Esau, Senior Director of Translational Research, as Vice President of Research and…
Read More...

Charles River Laboratories International declared that it has ventured into a definitive agreement to obtain MPI Research for $800 million in cash. James C. Foster, Chairman and…
Read More...

Leading provider of nonclinical contract research services and research models, Envigo asserted the appointment of Lynn Lewis to the position of  Senior Vice President, Global Sales.…
Read More...

U.S Food and Drug Administration paved way for the marketing of the Viz.AI Contact application which is a type of clinical decision support software designed to interpret computed…
Read More...

Leading clinical trial technology and specialty services provider, Bracket declared the appointment of Michael Nolte as the company's Chief Executive Officer. Michael Nolte served as…
Read More...

Precision medicine biotechnology company, developing targeted oncology therapeutics, Trovagene asserted the addition of two leading  institutions,Yale Cancer Center and principal…
Read More...

Martha A.Q .Curley, PhD, RN, FAAN, a professor in Nursing Science at the University of Pennsylvania's School of Nursing, has been appointed the Ruth M. Colket Endowed Chair in Pediatric…
Read More...

Astro's Interpretation of the Phase II CONDOR trial suggests that the immune checkpoint inhibitor durvalumab is tolerable among heavily pre-treated patients with recurrent or metastatic…
Read More...